Skip to content or footer

Our Team

We’ve brought together commercial leaders, researchers and biotechnology experts that will transform therapeutics development.

AmacaThera is a clinical-stage biotechnology company developing a novel drug delivery platform to improve patient outcomes across multiple therapeutic areas, including:

  • post-surgical pain management
  • cancer
  • other hard-to-reach targets

We’re developing products at the intersection of bio­ma­te­ri­als and pharmaceuticals.

Molecule yellow

Senior Management Team

Dr Mike Cooke v2
Dr. Mike Cooke
Co-Founder & CEO
PhD
Biomedical Engineer
Polymer design and drug delivery expert
Dr Molly Shoichet v2
Dr. Molly Shoichet
Co-Founder & Chief Science Officer
PhD
Chemical & Biomedical Engineer
Polymer design and drug delivery expert

Board of Directors

In addition to co-founders Mike Cooke and Molly Shoichet, our board is made up of the following:

Paul Austin v1 2x
Paul Austin
Founder, The P. Austin Family Foundation
JD
Lu han
Lu Han
Partner, Lumira Ventures
BSc, PhD
Michelle Scarborough v1
Michelle Scarborough
Managing Partner,
Strategic Investments and Women in Technology Fund, BDC
PhD

Recent News

RB Cx Profile Amaca Thera Blog Thumbnail scaled

RBCx features AmacaThera’s journey

Media Coverage

RBCx, the tech banking and investment arm of the Royal Bank of Canada, has featured AmacaThera’s drug development platform and start-up journey.
Read more

AmacaThera doses First In Human Study to Evaluate, AMT-143, for Non-opioid Treatment of Post-operative Pain

Press Release

AmacaThera Inc, a clinical stage biotechnology company specializing in the development of advanced sustained release hydrogel formulations, has dosed its first human subject with AMT-143, the company's lead asset in non-opioid acute pain management. Read more

AmacaThera Closes Series A Extension to Advance Clinical Development of Long Acting, Localized, Non-Opioid Therapeutics to Improve Post-Surgery Patient Care

Press Release

AmacaThera, a leader in the development of novel injectable, localized therapeutics based upon its AmacaGel delivery platform, announced the closing of a CAD$4.0 million financing round.Read more

See All Recent News